5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
|
| Active substance |
|
| Procedure number |
EMEA/H/A-31/1488
|
| Regulatory outcome |
Variation
|
| DHPC type |
Referral - Article 31
|
| Referral name |
Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
|
| Human ATC code |
|
| Dissemination date |
04/06/2020
|